Table 2. Tiagabine-induced change in [11C]flumazenil V T in control subjects.
| Dose Group I (0.15 mg/kg) | Dose Group II (0.25 mg/kg) | |||||||||
| Subdivision- Component ROIs | Baseline V T | Post-tiagabine V T | ΔV T(%) | d | p | Baseline V T | Post-tiagabine V T | ΔV T(%) | d | p |
| Association Cortex | 7.6±0.6 | 7.7±0.4 | 0.8±6.5 | −0.07 | 0.84 | 6.8±0.8 | 7.3±0.4 | 9.3±11.4 | −0.99 | 0.03 |
| -DLPFC | 7.6±0.6 | 7.6±0.4 | 0.5±6.0 | −0.03 | 0.92 | 6.7±0.8 | 7.2±0.4 | 9.5±11.2 | −1.00 | 0.03 |
| -Orbital Frt Ctx | 7.5±0.7 | 7.5±0.6 | 0.4±7.8 | −0.01 | 0.98 | 6.7±0.7 | 7.2±0.5 | 8.0±13.0 | −0.82 | 0.11 |
| -MPFC | 8.0±0.6 | 8.1±0.5 | 1.0±7.0 | −0.11 | 0.77 | 7.1±1.0 | 7.8±0.5 | 11.2±12.3 | −0.92 | 0.02 |
| -Ant. Cingulate Ctx | 7.8±0.6 | 8.0±0.5 | 2.9±7.9 | −0.38 | 0.36 | 7.2±0.8 | 7.7±0.5 | 7.5±11.3 | −0.72 | 0.08 |
| Sensory Cortex | 7.5±0.5 | 7.3±1.0 | −1.9±14.9 | 0.26 | 0.64 | 6.7±0.8 | 7.3±0.5 | 9.7±10.8 | −0.97 | 0.02 |
| -Parietal Ctx | 7.3±0.4 | 7.4±0.4 | 0.8±8.1 | −0.08 | 0.87 | 6.6±0.8 | 7.1±0.5 | 9.5±11.3 | −0.88 | 0.03 |
| -Occipital Ctx | 7.7±0.6 | 7.4±1.5 | −4.2±21.2 | 0.34 | 0.53 | 7.0±0.8 | 7.6±0.4 | 9.7±10.2 | −1.06 | 0.02 |
| Medial Temporal Lobe | 5.9±0.5 | 5.9±0.3 | 0.0±7.8 | 0.07 | 0.86 | 5.2±0.6 | 5.7±0.3 | 9.4±10.7 | −1.02 | 0.03 |
| -Amygdala | 5.9±0.6 | 5.8±0.4 | −0.6±10.1 | 0.14 | 0.73 | 5.2±0.6 | 5.6±0.4 | 8.0±12.0 | −0.79 | 0.11 |
| -Hippocampus | 6.0±0.5 | 5.9±0.3 | −1.1±8.3 | 0.23 | 0.58 | 5.1±0.5 | 5.6±0.4 | 10.1±10.6 | −1.15 | 0.02 |
| -Entor. Ctx | 5.6±0.4 | 5.6±0.3 | 0.9±7.9 | −0.09 | 0.84 | 5.1±0.7 | 5.5±0.3 | 9.7±11.6 | −0.83 | 0.03 |
| -Parahippocampus | 6.0±0.5 | 6.0±0.3 | 0.6±7.2 | −0.03 | 0.93 | 5.4±0.7 | 5.8±0.3 | 9.4±10.6 | −0.89 | 0.02 |
Values are Mean ± SD, in healthy controls (n = 9 per group); p is the significance level of the difference between the baseline and post-tiagabine scans in each group (paired t-test); d is the Cohen's effect size of this difference.